Somewhat Favorable Press Coverage Somewhat Unlikely to Affect MYOS RENS Technology (MYOS) Share Price
Headlines about MYOS RENS Technology (NASDAQ:MYOS) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MYOS RENS Technology earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8059349806462 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of MYOS RENS Technology (MYOS) traded down 4.93% on Friday, reaching $1.35. The company had a trading volume of 31,199 shares. The stock’s market capitalization is $7.89 million. The company’s 50 day moving average price is $1.39 and its 200-day moving average price is $1.94. MYOS RENS Technology has a 1-year low of $1.02 and a 1-year high of $6.98.
Separately, ValuEngine raised MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th.
MYOS RENS Technology Company Profile
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.